Phase 2 N=80 Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer
Lung Cancer
Primary: Overall Response Rate — 65; 50 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Phase 2 N=92 Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer
Lung Cancer
Primary: The Objective Overall Response — 7; 12; 7; 19 participants
Phase 2 N=82 Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
Recurrent Small Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Rovalpituzumab Tesirine — 0.4 mg/kg
Phase 2 N=50 Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer
Recurrent Small-cell Lung Cancer (SCLC) · Lung Cancer, Small Cell
Primary: Percentage of Participants With Progression-free Survival (PFS) at 3 Months — 65 percentageof participants — p=0.017
Phase 2 N=25 AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Primary: Objective Response Rate — 0; 0 percentage of responding patients
Phase 2 N=25 Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: 8-Week Progression-Free Rate — 0.0; 8.3 percentage of participants
Phase 2 N=60 Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer
Lung Cancer
Primary: Number of Grade 3/4 Toxicities Patients Experienced on Maintenance Bevacizumab Following Chemoradiation for Limited Stage - Small Cell Lung Cancer (LS-SCLC) — 2; 1; 1; 1…
Phase 2 N=26 Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: Objective Response Rate — 6 Participants
Phase 2 N=13 M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
Carcinoma, Small Cell · Lung Cancer · Small Cell Lung Cancer
Primary: Proportion of Evaluable Participants Who Experience a Partial Response (PR) or Complete Response (CR) Reported Along With an 80% Confidence Interval. — 0.1; 0; 0.2; 0…
Phase 2 N=37 Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
Lung Cancer
Primary: Response by RECIST Criteria (v 1.0) — 3; 5; 11; 15 participants
Phase 2 N=50 Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Lung Cancer
Primary: Patient Response — 2; 1; 2; 27 participants
Phase 2 N=19 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response Rates (Complete and Partial) Evaluated Using RECIST Criteria — 2 participants
Phase 2 N=44 Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
Extensive Stage Small Cell Lung Cancer · Limited Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: 6 Week Progression Free Survival — 43 percentage of participants
Phase 2 N=38 Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
Recurrent Small Cell Lung Carcinoma
Primary: 18 Week Progression-free Survival Rate — 35; 72 percentage of participants
Phase 2 N=45 Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
Urothelial Carcinoma · Urothelial Cancer · Lung Neoplasms
Primary: Phase I: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of EP0057 (CLRX101) in Participants With Refractory Cancers. — 12 mg/m^2
Phase 2 N=37 BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Phase 2 N=153 Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
Limited Stage Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 14.5; 10.7 months
Phase 2 N=33 Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
Small Cell Lung Cancer
Primary: Progression Free Survival — 11 months
Phase 2 N=50 Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Lung Cancer
Primary: Time to Progression — 123 days
Phase 2 N=55 Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
Carcinoma, Small Cell · Small Cell Lung Cancer
Primary: Objective Response Rate — 3 Participants
Phase 2 N=89 Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response (Confirmed and Unconfirmed, Complete and Partial Responses Per RECIST) — 11; 2 percentage of participants
Phase 2 N=40 Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: Determine the Proportion of Previously Treated Small Cell Lung Cancer (SCLC) Patients Whose Disease Has Not Progressed Following 6-weeks (2 Cycles) of Treatment With…
Phase 2 N=39 A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
Lung Cancer · SCLC
Primary: Phase I: Maximum Tolerated Dose (MTD) — 30 mg/m^2
Phase 2 N=37 Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: One-year Survival, The Percentage of Patients Who Are Alive One Year After Completing Protocol Treatment — 54 percentage of participants
Phase 2 N=33 Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
Small Cell Lung Cancer · Lung Cancer · SCLC
Primary: 8-Week Progression-Free Rate — 0.567 proportion of patients
Phase 2 N=32 Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: Phase I Toxicity Based Upon Adverse Events Clasified by the NCI Common Terminology Ctireria Version 2.0 (Phase I) — 3; 1; 1; 1 participants
Phase 2 N=80 A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
Extensive-Stage Small Cell Lung Cancer
Primary: 1-year Survival — 38 percentage of participants
Phase 2 N=61 Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Carcinoma, Small Cell
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 57 percentage of participants
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months